This report is primarily concerned with developments, market trends and regulations within the Japanese cell technology, cell therapy, tissue engineering and gene therapy sectors. It begins by outlining Japan's academic landscape and key research hubs within these various fields. It then analyses in detail the Japanese Society for Regenerative Medicine and also examines Japanese government policy and regulations regarding this topic. This report also provides a comparative analysis of EU, Japanese and US regulations, as well as a list of opportunities, access points and potential obstacles for EU SMEs hoping to enter this market in Japan.
Professor Rolf Schmid is a consultant with over 40 years’ experience in biotechnology-related R&D and business. Click here to access his profile.
How is Japanese biotech R&D structured, who are the key stakeholders, and how can European SMEs profit and find Japanese partners? Japan spends consistently over 3% of its GDP on R&D, of which some 70
This website and related activities are managed by the EU-Japan Centre for Industrial Cooperation, a joint venture between the European Commission's Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) and the Japanese Government's Ministry of Economy, Trade & Industry (METI).
Hundreds of web pages with up-to-date information on Japan, more than 400 market reports and recorded webinars available as well as a lot of detailed information on Japanese business culture.